← signals
2026-08-11·TSM·foundry capacity announcement
lowup

TSMC's July 2026 revenue came in at NT$467.58 billion ($14.5B), up 44.7% year-on-year, exceeding the company's...

TSMC's July 2026 revenue came in at NT$467.58 billion ($14.5B), up 44.7% year-on-year, exceeding the company's already-bullish 2026 growth guide of ~40%.

window 45devidence 17confidence score 100price TSM $418.47

confidence score

Strong evidence: 3 independent source classes support this read.

100
low confidence3 independent source classesnewsmarketpasses publish gate
priced-in check

TSM has not made a large direction-matching 30-90 day move yet.

not priced in
as of 2026-08-107d n/a45d n/a90d +6%yahoo

signal brief

TSMC's July 2026 revenue came in at NT$467.58 billion ($14.5B), up 44.7% year-on-year, exceeding the company's already-bullish 2026 growth guide of ~40%. According to CNBC, high-performance computing—where AI chip sales are booked—accounted for 66% of revenue in Q2. TSMC also raised its 2026 capex projection to $60-64 billion, signaling continued aggressive capacity expansion for advanced nodes. This is a direct positive for the AI-infra supply chain: TSMC's foundry output feeds Nvidia, Google's TPUs, and other AI accelerators. The revenue beat suggests AI demand remains robust despite recent capex-jitter sell-offs in semiconductor stocks. Separately, Digitimes reports TSMC affiliate VisEra is scaling 1.6T silicon photonics production, further evidence of AI infrastructure investment in optical interconnects.

What the sources said:

  • "TSMC is now guiding for 40% growth in revenues for this year, so July's numbers put it ahead of that figure" – CNBC
  • "AI-related demand continues to be extremely robust," said TSMC Chairman C.C. Wei – CNBC
  • "TSMC also raised its capital expenditure projection to between $60 billion and $64 billion for this year" – CNBC
  • Digitimes headline only: 'TSMC affiliate VisEra scales AI optics with 1.6T silicon photonics' – Digitimes

source data used

spillover entities

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.